Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • The increase in the stock of cancer drugs from 1975 to 1995 accounted for about 50 to 60 percent of the increase in age-adjusted survival rates in the first 6…  
  • Use of tamoxifen, a drug used to treat breast cancer, has resulted in a direct cost savings of $41,372 per year of life gained in women 35- to 49-years-old, $68,349…  
  • Gains in healthy years of life and social value from cancer R&D
     
  • A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in…